120
Participants
Start Date
August 4, 2017
Primary Completion Date
January 31, 2021
Study Completion Date
December 31, 2024
R-CHOEP
rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
DA-EPOCH-R
dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
Dept of Haematology, Rigshospitalet, Copenhagen
Dept of Haematology, Sjaellands University hospital, Roskilde, Roskilde
Dept. of Haematology and Oncology, Helse Stavander HF sykehuset, Stavanger
Dept haematology, Odense University hospital, Odense
Dept. of Oncology, Helse Bergen HF Haukeland sykehus, Bergen
Dept of Oncology, St. Olavs hospital HF, Trondheim
Dept. of Oncology, Universitetssykehuset i Nord-Norge HF, Tromsø
Turku University Hospital, Syöpäklinikka, Turku
TAYS, Tampere
Keski-Suomen keskussairaala, Jyväskylä
Kuopio University Hospital, Kuopio
Aarhus University Hospital, Aarhus
Dept of Haematology, Herlev Hospital, Copenhagen, Herlev
Oslo University Hospital, Oslo
Skåne University Hospital, Lund
Helsinki University Hospital Cancer Centre, Helsinki
Helsinki University Central Hospital
OTHER
Aarhus University Hospital
OTHER
Nordic Lymphoma Group
NETWORK